Onychomycosis is a fungal infection of the nail and nail bed that affects around 35 million people in the US.
In July, Anacor entered into an exclusive agreement with Sandoz, a Novartis company, to distribute and commercialize its Kerydin in the US.
Anacor chairman and chief executive officer Paul Berns said the company is happy to announce the commercial launch of its first approved product, Kerydin, through PharmaDerm, the branded dermatology division of Sandoz.
"We have been working closely with the team at PharmaDerm and are confident in their ability to commercialize Kerydin in the US," Berns said.
Anacor is focused on discovering, developing and commercializing new small-molecule therapeutics derived from its boron chemistry platform.
The company’s lead product candidate is AN2728, an investigational anti-inflammatory PDE-4 inhibitor being developed to treat mild-to-moderate atopic dermatitis and psoriasis.